| 11.93 0.33 (2.84%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.99 | 1-year : | 19.68 |
| Resists | First : | 14.55 | Second : | 16.85 |
| Pivot price | 11.89  |
|||
| Supports | First : | 10.82 | Second : | 9.01 |
| MAs | MA(5) : | 11.4 |
MA(20) : | 11.98 |
| MA(100) : | 15.93 |
MA(250) : | 10.25 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 23.1 |
D(3) : | 15.5 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 26.95 | Low : | 3.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRVS ] has closed below upper band by 48.8%. Bollinger Bands are 65.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.34 - 12.38 | 12.38 - 12.42 |
| Low: | 11.38 - 11.44 | 11.44 - 11.48 |
| Close: | 11.85 - 11.93 | 11.93 - 12 |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Sat, 13 Jun 2026
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Sat, 13 Jun 2026
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Yahoo Finance
Fri, 12 Jun 2026
Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes - Stock Titan
Tue, 09 Jun 2026
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
Fri, 05 Jun 2026
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Tue, 02 Jun 2026
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 85.1 (%) |
| Shares Short | 18,910 (K) |
| Shares Short P.Month | 16,930 (K) |
| EPS | -0.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -30.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -21.7 |
| PEG Ratio | 0 |
| Price to Book value | 4.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|